Velosity Acquires Lucid Labs to Bolster Medtech Engineering

Velosity has acquired engineering and precision machining company Lucid Labs, growing its ability to support medical device manufacturers from product development through commercialization.

Based in Rogers, Minn., Lucid Labs has partnered with leading medtech OEMs for over two decades, supporting medical technology design, development, and commercialization. The acquisition allows Velosity to engage earlier in the product lifecycle, supporting concept development, prototyping, design refinement, manufacturability and production.

The expanded services cover product development, embedded engineering and rapid prototyping, including concept development, design optimization, design for manufacturability, fixture and process development, CNC and Swiss machining, 3D printing, functional prototypes, and short-run production.

These capabilities complement Velosity’s existing expertise in tooling, injection molding, precision machining, assembly, and packaging, supporting customers from early development through manufacturing readiness and full-scale production.

The combined company’s embedded engineering teams will work directly with customers to evaluate designs, develop prototypes, and prepare products for manufacturing. Lucid’s rapid prototyping capabilities also augments the Velosity Engineering, Launch and Optimization Lab, a specialized precision machining development center located in the company’s Brooklyn Park, Minn. facility.

Tim Hillukka, Lucid’s founder and CEO, will join the merged company as chief innovation officer. He will head ideation and innovation across the combined user base.

Comments from Velosity and Lucid Labs execs

Hillukka: “Joining Velosity creates a unique opportunity to combine Lucid’s innovative, industry-leading product development expertise with world-class manufacturing capabilities. We are engaging with customers sooner, solving more complex challenges, and delivering innovative medical technologies to the market faster.”

Velosity chief commercial officer Darren Bjork: “Bringing Lucid Labs together with Velosity creates a connected path from concept to commercialization. Together, we can help customers solve challenges earlier, accelerate development and transition more seamlessly into manufacturing, helping innovative technologies reach clinicians and patients sooner.”

Velosity CEO Dave Hemink: “Our goal has always been to accelerate innovation for our customers. The addition of Lucid Labs expands our ability to engage earlier, solve complex challenges and support customers throughout the product lifecycle, creating a more connected path to commercialization and a much deeper understanding of strategy and portfolio trajectory.”

Learn more about Velosity here.